Risks Emerge for New Class of Diabetes Drugs

A new class of diabetes drugs that has been available for a little over three years have become immensely popular with doctors and patients, even though the pills have a host of adverse events and risks.

The first SGLT2 (first sodium-glucose cotransporter-2) inhibitor to hit the market, back in 2013, was Invokana (canagliflozin). Since then, the FDA has granted approval to 2 other oral medications in this class, Farxiga (dapagliflozin) and Jardiance (empagliflozin). By the fourth quarter of 2015, the trio accounted for 2 million prescriptions, an amazing six-fold increase since the first quarter of 2014, according to IMS Health.

Despite their growing popularity, SGLT2s have been associated with many adverse event reports and other troubling side effects based on clinical trials, according to a new report from the Institute for Safe Medication Practices (ISMP). These include: life-threatening ketoacidosis; electrolyte imbalances leading to severe dehydration and other problems; acute kidney injury; frequent genital infections, primarily fungal; and increased risk of bone fracture.

For example, interim data from a cardiovascular outcomes trial for Inovkana released in January found that the drug caused a statistically significant increased risk of bone fracture (4.0% v. 2.6%) compared to a placebo group treated with other medications. There was also an increased risk of foot and toe amputation from the same trial.

ISMP also found emerging signals of three other adverse effects: possible increased risk of limb amputation; pancreatitis; and hypersensitivity. They added that the number of cases increased for other reported adverse effects, especially sepsis and urosepsis, kidney stones. and abnormal weight loss.

Last month, the FDA strengthened the warnings on SGLT2 drugs regarding acute kidney injury “based on recent reports.”


Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?

No votes so far! Be the first to rate this post.


Latest News

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

We knew it was too good to be true – free and cheap drugs aren’t worth it. Also, taking a magic pill to lose weight could give you cancer (!). One ray of sunshine: a pain therapy device using shortwave is now available over-the-counter. Have a lovely Valentine’s Day! Be…

Flouride, PPIs, Breast Density and Prostate Cancer

Flouride, PPIs, Breast Density and Prostate Cancer

Startling news about fluoride, a study encourages more limites use of PPIs, does knowing the density of your breasts matter, and vegetables aren’t helpful in warding off prostate cancer (darn).  Be Well.  Fluoride and Pregnancy The medical community was shocked at the conclusions of two new studies on fluoride’s effect…

  • Advertisement